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Influenza is responsible for a seasonal epidemic every 
winter in the Northern hemisphere, with a great impact 
on then health system due to morbidity, mortality and 
health services use. Influenza surveillance include 
monitoring annual epidemics, detection of the start and 
duration of the epidemic in order to alert health services 
to reduce morbidity and economic impact. Influenza 
surveillance based on drug dispensation, health services 




Since 1988, in Catalonia, a region of Spain with 7.5 
million inhabitants, influenza surveillance is carried out 
using the information obtained from an influenza 
surveillance system based on sentinel physicians, and 
from medical visits and hospitalizations due to 
influenza.
[3,4] 
Traditional influenza surveillance 
information systems provide information on the week of 
start and duration of the influenza epidemic, and 
influenza morbidity. Nevertheless, traditional influenza 
surveillance systems do not provide information about 
influenza morbidity not attended in health centres and 
medications used to treat influenza-like cases. 
 
In 2017, a new influenza syndromic surveillance system 
based on sentinel pharmacies was developed in 
Catalonia.
[5] 
The objective of this new sentinel 
surveillance system was to obtain information about the 
influenza epidemic and medications dispensed to patients 
with influenza-like illness during the influenza season. 
The aim of this study was to analyse influenza 
surveillance data obtained using a new influenza sentinel 
surveillance system based on sentinel pharmacies of 
Catalonia during the 2017-2018, 2018−2019 and 2019-
2020 influenza seasons.  
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ABSTRACT 
 
Objective: To analyse influenza surveillance data obtained from sentinel pharmacies 
of Catalonia, Spain, in 2017−18, 2018−19 and 2019-20 influenza seasons. Methods: 
Influenza surveillance information was collected from a representative sample of 
community pharmacies of Catalonia. Influenza-like cases were identified based on the 
ECDC criteria.The Chi-square test and Odds ratios were used to compare percentages 
between different population groups, with a p <0.05 considered as statistically 
significant. The screening method was used to assess influenza vaccination 
effectiveness. The moving epidemic method (MEM) was used to assess influenza 
epidemics in the three influenza seasons. Results: A total of 836, 1,000 and 587 
influenza-like cases were reported in 2017−18, 2018−19 and 2019−20. Sentinel 
pharmacies dispended medications to 94-98% of patients. Paracetamol, cough 
medication, ibuprofen and antihistamines were dispended to more than 25% of 
patients. Dispensation of antibiotics decreased by 57% from 2017-18 to 2019-20 (OR = 
0.45, 95% CI: 0.28-0.74, p < 0.001). Physicians prescribed medications to 30-38% of 
influenza-like patients. The influenza vaccination effectiveness in individuals aged 65 
or more years was 51.4% (95% CI: 41.9−60.7) in 2018-19 and 67% (95% CI: 
53.4−79.8) in 2019-20 influenza seasons. Influenza epidemics occurred from week 50 
of 2017 to week 7 of 2018; from week 51 of 2017 to week 8 of 2019; and from week 2 
to week 7 of 2020. Conclusion: The influenza surveillance system based on sentinel 
pharmacies provided consistent information on the influenza epidemic, influenza 
morbidity not assisted in health centres and medications used to treat influenza-like 
cases during 2017−2019. 
 
KEYWORDS: Influenza surveillance, influenza morbidity, influenza medications 
dispensed, sentinel pharmacies, influenza vaccination. 
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METHOD 
 
Influenza syndromic surveillance 
Influenza surveillance information was collected from a 
representative sample of community pharmacies of 
Catalonia, a region of Spain with 7.5 million inhabitants. 
Fifty pharmacies were selected randomly from the list of 
community pharmacies located in the four provinces of 
Catalonia: 33 (66%) pharmacies were selected from 
Barcelona, 7 (14%) from Tarragona, 7 (14%) from 
Girona, and 3 (6%) from Lleida. The distribution of 
pharmacies by province was proportional to the 
distribution of the population of Catalonia by province: 
73.8% from Barcelona, 10% from Tarragona, 10.6% 




Influenza syndromic surveillance activity developed by 
sentinel pharmacies participating in the study consisted 
in: 1) to detect influenza-like patients among individuals 
attended during the 2017-18, 2018-19 and 2019-20 
influenza seasons, and 2) to collect socio-demographic 
and health information from influenza-like patients.  
 
Sentinel pharmacies declared and collected health 
information from all patients with influenza-like illness 
attended from week 40 to week 20 of next year during 
2017-18, 2018-19 and 2019-20 influenza seasons. 
Influenza-like cases were detected by active 
epidemiological surveillance based on the four criterion 
of the European Centre for the Prevention and the 
Control of Illnesses (ECDC):
7
1) sudden onset of 
symptoms, 2) fever, 3) at least one of the four systemic 
symptoms: malaise, headache, myalgia, 4) at least one of 
three respiratory symptoms: cough, sore throat, shortness 
of breath.  
 
Data collection 
A new surveillance system was developed by the Public 
Health Agency of Catalonia to obtain information on 
influenza epidemic from a representative sample of 
pharmacies of Catalonia. An anonymous questionnaire 
without any personal information was used to collect 
socio-demographic and health information from all 
influenza-like patients attended by pharmacies 




included the age and sex. Health information collected 
included: 1) symptoms of influenza used to detect 
influenza-like cases, 2) detection of cases by sentinel 
pharmacies or in a previous medical visit, 3) medications 
dispensed by sentinel pharmacies to influenza-like 
patients, 3) medications prescribed by physicians, 4) 
derivation of patients to primary health care centres, and 
5) influenza vaccination ≥ 14 days before symptoms 
onset (2018-19 and 2019-20).   
 
Statistical analysis 
Sociodemographic characteristics of influenza-like cases, 
detection of influenza by sentinel pharmacies and 
medical visits, medications dispensed by pharmacies, 
medications prescribed by physicians, derivation to 
health centres, and influenza vaccination status were 
assessed in the three influenza seasons. Percentages and 
95% confidence intervals were determined for qualitative 
variables. The Chi-square test (Fisher’s exact test when 
necessary) and the odds ratios were used to compare 
percentages in different groups, considering a p<0.05 as 
statistically significant. The t-test was used to compare 
means between different population groups, with a p 
<0.05 considered as statistically significant. The 
statistical analysis of the results was carried out using 
IBM-SPSS Version 18 (IBM-SPSS, Chicago, IL, USA).  
 
The effectiveness of influenza vaccination (VE) in 2018-
19 and 2019-20 among individuals aged ≥ 65 years and 
95% confidence intervals were calculated using the 
screening method.
[8]
 The influenza vaccination 
effectiveness (VE) was determined  using the formula: 
VE = (PV – PCV)/(PV (1 – PCV)). In this formula, PV is 
the proportion population vaccinated, and PCV is the 
proportion of cases aged ≥ 65 years vaccinated against 
influenza.  
 
Influenza epidemics during 2017-18, 2018-19 and 2019-
20 were analysed using the information on the number of 
influenza-like cases reported per week by sentinel 
pharmacies. The moving epidemic method (MEM)
9
 was 
used to analyse influenza epidemics. Firstly, the start and 
duration of influenza epidemics in 2017-18 and 2018-19 
were determined splitting the season in three periods 
based on the MEM: pre-epidemic, epidemic, and post-
epidemic. Secondly, the epidemic threshold (cases 
declared per week) for detecting the start and duration of 
the 2019-20 influenza epidemic was determined using 
the MEM method from the pre-epidemic and post-




The study was approved by the Public Health Agency of 
Catalonia and the Consell de Col·legis de Farmacèutics 
de Catalunya. Verbal informed consent was obtained 
from all influenza-like patients or their parents to 
participate in the study and collect sociodemographic and 




Forty one pharmacies participated during the 2017−18 
and 2018−19 influenza seasons, and 35 participated in 
the 2019-20 influenza season. The participation rate was 
82% 2017−18 and 2018−19 and 70% 2019−20. The 
distribution of sentinel pharmacies by province in 
2017−18 and 2018−19 was: 25 (61%) from Barcelona, 7 
(17.1%) from Tarragona, 6 (14.6%) from Girona and 3 
(7.3%) from Lleida. The distribution of sentinel 
pharmacies by province in 2019−20was: 21 (60%) from 
Barcelona, 6 (17.1%) from Tarragona, 5 (14.2%) from 
Girona and 3 (8.6%) from Lleida. There were not 
statistical differences between the distribution of 
pharmacies by province obtained in the study and the 
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Eight hundred thirty six, 1,000 and 587 influenza-like 
cases were reported by sentinel pharmacies to the 
influenza syndromic surveillance system during 
2017−18, 2018−19 and 2019−20 influenza seasons, 
respectively (Table 1).The mean age of influenza-like 
cases was 44 years (44.4 years in men and 43.7 years in 
women) in 2017−2018; 40.9 years (39.9 years in men 
and 41.9 years in women) in 2018−19; and 44 years 
(36.8 years in men and 39 years in women) in 2029−20. 
The percentages of male and female cases were 46.7 and 
53.3% in 2017−18; 48% and 52% in 2018−19; and 
46.7% and 53.3% n 2018−19. Seventy seven percent of 
cases in 2017−18, 79% in 2018−19 and 73.1% in 
2019−20 had 15 to 64 years (Table 1).   
 
The percentage of cases aged 15-64 years declared by 
sentinel pharmacies in 2017−18 was higher than in 
2018−19 and 2019−20, but differences were not 
statistically significant (Table 1). The percentage of 
cases aged ≥ 65 years declared by sentinel pharmacies in 
2019−20 was lower than in 2017−18 and2018−19, but 
differences were not statistically significant. The 
percentage of cases aged 0-4 years declared by sentinel 
pharmacies in 2019−20 was significantly higher (p < 
0.001) than in 2017−18 (OR = 6.16; 95% CI: 2.87-13.2) 
and2018−19 (OR = 2.78; 95% CI: 1.60-4.81).  
 
The percentage of cases aged 15-64 years declared by 
sentinel pharmacies was significantly higher than the 
percentage of cases in other age groups for both sexes, 
men and women in the three influenza seasons (Table 1). 
The Odds ratios for influenza cases aged 15-64 years 
versus influenza cases in other age groups were: 14.90 
(95% CI: 11.75−18.89, p < 0.001) in 2017−18; 11.59 
(95% CI: 9.40−14.29, p < 0.001) in 2018−19;and 7.37 
(95% CI: 5.70−9.59, p < 0.001) in 2019−20. The 
percentage of cases aged 5-14 years declared by sentinel 
pharmacies was significantly higher than the percentage 
of cases aged 0-4 years for both sexes, men and women 
in the three influenza seasons (Table 1). The Odds ratios 
for influenza cases aged 5-14 years versus influenza 
cases aged 0-4 years were:5.47 (95% CI: 2.60−11.55, p < 
0.001) in 2017−18; 4.44 (95% CI: 2.75−7.18, p < 0.001) 
in 2018−19;and 2.19 (95% CI: 1.43−3.38, p < 0.005) in 
2019−20.The percentage of cases aged ≥ 65 years 
declared by sentinel pharmacies was significantly higher 
than the percentage of cases aged 0-4 years for both 
sexes, men and women in the three influenza seasons 
(Table 1). The Odds ratios for influenza cases aged ≥ 65 
years versus influenza cases aged 0-4 years were: 16.23 
(95% CI: 7.98−33.0, p < 0.001) in 2017−18; 6.29 (95% 
CI: 3.94−10.06, p < 0.001) in 2018−19;and 1.80 (95% 
CI: 1.16−2.81, p < 0.01) in 2019−20.   
 
Figure 1 presents the 2017−18 and 2018−19 influenza 
curves and the results of the MEM analysis. Based on the 
MEM method, the influenza epidemic started on week 50 
of 2017 and ended on week 7 of 2018 in the 2017−18 
influenza season, and started on week 51 of 2018 and 
ended on week 8 of 2019 in the 2018−19 influenza 
season. The influenza epidemic peaks were achieved on 
week 2 of 2018 and week of 2019 in the 2017−18 and 
2018−19 influenza seasons, respectively. The thresholds 
for influenza epidemic intensity in terms of influenza-
like cases declared per week by sentinel 
pharmaciesobtained for the 2019−20 influenza season 
using the influenza syndromic surveillance information 
obtained in the 2017−18 and 2018−19 influenza seasons 
were: 29.79 cases for basal influenza epidemic; 51.63 for 
medium influenza epidemic intensity; 133.8 for high 
influenza epidemic intensity; and 203.7 for very high 
influenza epidemic intensity. In the 2019−20 influenza 
season, the influenza epidemic started on week 2 (> 29 
cases) and ended on week 7 (> 29 cases) of 2020 (Figure 
2). The influenza epidemic peak was achieved on week 5 
of 2020 in the 2019−20 influenza season.   
 
In the three influenza seasons, most influenza-like cases 
declared by sentinel pharmacies had not been detected 
previously in a medical visit (Table 2). Seventy seven 
percent of influenza-like cases in 2017-2018, 68.7% in 
2018-2019 and 61.8% in 2019-2020 were detected by 
sentinel pharmacies (Table 2).The Odds ratios 
forinfluenza detection by sentinel pharmacies versus 
influenza detection by physicians in a medical visits 
were: 4.80 (95% CI: 3.90−5.90, p < 0.001) in 2017−18; 
4.27 (95% CI: 3.54−5.15, p < 0.001) in 2018−19;and 
2.62 (95% CI: 2.07−3.32, p < 0.005) in 2019−20.In the 
three influenza seasons, the percentage of influenza 
detection by sentinel pharmacies was higher in 
individuals aged 15-64 years than in individuals aged 5-
14 years and ≥ 65 years, but differences were not 
statistically significant. The percentage of influenza 
detection by sentinel pharmacies in individuals aged 0-4 
years was significantly lower (p < 0.001) than in 
individuals aged 15-64 years in the three influenza 
seasons, and it was significantly lower (p < 0.05) than in 
individuals aged ≥ 65 years in 2017-18 and 2018-19. 
 
Sentinel pharmacies dispended medications to 787 
(94.1%) patients in 2017-18, 953 (95.3%) patients in 
2018-19 and 578 (98.5%) patients in 2019-20 (Table 3). 
The four medications more frequently dispended to 
influenza-like patients in the three studied influenza 
seasons were paracetamol, cough medications, ibuprofen 
and antihistamines (Table 4). Paracetamol was dispended 
to 72.4% of influenza-like patients in 2017-18, 75% of 
patients in 2018-19 and 83.8% of patients in 2019-20. 
Cough medications were dispended to 44.7% of patients 
in 2017-18, 32.8% of patients in 2018-19 and 38.5% of 
patients in 2019-20. Ibuprofen was dispended to 27.6% 
of patients in 2017-18, 27% of patients in 2018-19 and 
29% of patients in 2019-20. Antihistamines were 
dispended to 31.9% of patients in 2017-18, 23.7% of 
patients in 2018-19 and 19.4% of patients in 2019-20. 
Other medications were dispensed to 0.2-13% of patients 
(Table 4). Antibiotics were dispended to 7.9% of patients 
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in 2017-18, 7.2% of patients in 2018-19 and 3.7% of 
patients in 2019-20.  
 
The dispensation of medications to influenza-like 
patients was quite similar in 2017-18, 2018-19 and 2019-
20 influenza seasons, except for antibiotics, paracetamol, 
cough medication and antihistamines (Table 4). 
Dispensation of antibiotics decreased by 57% from 2017-
18 to 2019-20; dispensation of paracetamol increased 
15.7% from 2017-18 to 2019-20; dispensation of cough 
medication decreased by 13.9% from 2017-18 to 2019-
20; and dispensation of antihistamines decreased by 
39.2% from 2017-18 to 2019-20. The Odds Ratio 
comparing the dispensation of medications in 2019-20 
and 2017-18 was 0.45 (95% CI: 0.28−0.74, p < 0.005) 
for antibiotics; 1.97 (95% CI: 1.51−2.98, p < 0.001) for 
paracetamol; 0.77 (95% CI: 0.62−0.96, p < 0.05) for 
cough medication; and 0.51 (95% CI: 0.40−0.66, p < 
0.001) for antihistamines.  
 
Physicians had prescribed medications to 253 (30.3%) 
patients with influenza-like illness attended by sentinel 
pharmacies in 2017-18, 344 (34.4%) in 2018-19 and 225 
(34.3%) in 2019-20 (Table 5). The three medications 
more frequently prescribed by physicians in the three 
studied influenza seasons were paracetamol, cough 
medication and ibuprofen (Table 6). Paracetamol was 
prescribed to 21.9% of influenza-like patients in 2017-
18, 24.9% of patients in 2018-19 and 30.8% of patients 
in 2019-20. Cough medications were prescribed to 12% 
of patients in 2017-18, 8.1% of patients in 2018-19 and 
9.9% of patients in 2019-20. Ibuprofen was prescribed to 
11.1% of patients in 2017-18, 12.8% of patients in 2018-
19 and 17% of patients in 2019-20. Other medications 
were prescribed to 0.1-7% of patients (Table 6). The 
prescription of antibiotics decreased by 57% from 2017-
19 to 2018-19. The prescription of antibiotics was 
significantly lower in 2019-20 than in 2017-18 (OR = 
0.45, 95% CI: 0.28−0.74, p < 0.005) and 2018-19 (OR = 
0.50, 95% CI: 0.31−0.82, p < 0.005). Oseltamivir was 
prescribed to 0.4% of patients in 2017-18, 1% of patients 
in 2018-19 and 1% of patients in 2019-20.  
 
The prescription of medications to influenza-like patients 
was quite similar in 2017-18, 2018-19 and 2019-20 
influenza seasons, except for antibiotics, paracetamol, 
ibuprofen, and antihistamines (Table 6). Prescription of 
antibiotics decreased by 57% from 2017-18 to 2019-20; 
prescription of paracetamol increased 40.6% from 2017-
18 to 2019-20; prescription of ibuprofen increased by 
62.2% from 2017-18 to 2019-20; and prescription of 
antihistamines decreased by 49.1% from 2017-18 to 
2019-20. The Odds Ratio comparing the prescription of 
medications in 2019-20 and 2017-18 was 0.45 (95% CI: 
0.28−0.74, p < 0.005) for antibiotics; 1.59 (95% CI: 
1.25−2.02, p < 0.005) for paracetamol; 1.64 (95% CI: 
1.21−2.20, p < 0.005) for ibuprofen; and 0.50 (95% CI: 
0.28−0.85, p < 0.05) for antihistamines.  
Sixty-six (6.6%) in 2018−19 influenza season and 33 
(5.6%) in 2019−20 influenza season had received the 
current influenza vaccine during the influenza season. 
The average age of vaccinated patients was of 61.2 years 
(63 years in men and 60.3 years in women) in 2018−19, 
and 54.7 years (51.8 years in men and 57.2 years in 
women) in 2019−20.The influenza vaccination coverage 
increased significantly (p < 0.001) with age in the 
2018−19 and 2019−20 influenza seasons In the 2018−19 
influenza season, the influenza vaccination coverage 
increased significantly from 0% in children aged 0-14 
years to 33.6% in individuals aged 65 or more years. In 
the 2019−20 influenza season, the influenza vaccination 
coverage increased significantly from 0% in children 
aged 0-14 years to 26.3% in individuals aged 65 or more 
years. The influenza vaccination coverage was 
significantly higher (p < 0.001) in individuals aged 65 or 
more years than in other age groups in 2018−19 and 
2019−20.  
 
In the 2018−19 influenza season, 40 (60.6%) patients 
had received the influenza vaccine for the 
recommendation addressed to people of 65 or more 
years; 6 (9.1%) patients for the recommendation 
addressed to people with high risk of influenza 
complications: 1 (1.5%) patient for the recommendation 
addressed to pregnant women; 10 (15.2%) patients for 
the recommendation addressed to health personnel; 1 
(1.5%) patient for the recommendation addressed to 
carers of people of high risk; and 8 (12.1%) patients had 
received the influenza vaccine for personal reasons. In 
the 2019−20 influenza season, 14 (42.4%) patients had 
received the influenza vaccine for the recommendation 
addressed to people of 65 or more years; 4 (12.1%) 
patients for the recommendation addressed to people 
with high risk of influenza complications: 3 (9.1%) 
patient for the recommendation addressed to pregnant 
women; 4 (12.1%) patients for the recommendation 
addressed to health personnel; and 8 (24.3%) patients 
had received the influenza vaccine for personal reasons. 
 
The effectiveness of influenza vaccination obtained in 
this study for individuals aged ≥ 65 years in Catalonia 
was 51.4% (95% CI: 41.9-60.7%) during the 2018-19 
influenza season and 67.1% (95% CI: 53.5-79.8%) 
during the 2019-20 influenza season (Table 7). Influenza 
vaccination effectiveness was determined in this study 
using the information about the vaccination coverage in 
individuals aged ≥ 65 years in Catalonia in 2018-19 
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Table 1: Distribution of patients with influenza-like illness by age and sex in Catalonia (Spain) in the 2017-2018 
2018-2019 and 2019-2020 influenza seasons. 
 
 Total Men Women 
Age No.     % (95% CI) No.      % (95% CI) No.      % (95% CI) 
2017-2018 influenza season 
0-4 years 8     1.0 (0.2-1.7) 4      1.0 (0.3-2.6) 4      0.9 (0.2-2.3) 
5-14 years 42     5.0 (3.5-6.6) † 21     5.4 (3.0-7.7) † 21     4.7 (2.6-6.8) ¶ 
15-64 years 664   79.4 (76.6-82.2)* 308   79.0 (74.8-83.1)* 356   79.8 (76.0-83.7)* 
≥ 65 years 122   14.6 (12.1-17.0)**, λ 57   14.6 (11.0-18.2) ‡ 65   14.6 (11.2-18.0)*** 
Total 836   100 390   100 446   100 
2018-2019 influenza season 
0-4 years 21     2.1 (1.2-3.0) 13     2.7 (1.1-4.3) 8     1.5 (0.4-2.7) 
5-14 years 87     8.7 (6.9-10.5) ¶ 48   10.0.4 (7.2-12.8) † 39     7.5 (5.1-9.9) § 
15-64 years 773  77.3 (74.6-79.9)* 365   76.0 (72.5-79.1)* 408   78.5 (74.8-82.1)* 
≥ 65 years 119  11.9 (9.8-14.0)**, λ 54   11.2 (8.3-14.2) ** 65   12.5 (9.6-15.4) 
Total 1,000   100 480   100 520   100 
2019-2020 influenza season 
0-4 years 33     5.6 (3.7-7.6) 18     6.4 (3.3-9.4) 15     4.9 (2.3-7.5) 
5-14 years 68   11.6 (8.9-14.3) ¶ 37   13.1 (9.0-17.2) † 31   10.2 (6.6-13.9) § 
15-64 years 429  73.1 (69.4-76.7)* 204   72.1 (66.7-77.5)* 225   74.0 (68.9-79.1)* 
≥ 65 years 57    9.7 (7.2-12.2)**, λ 24     8.5 (5.1-11.9) ‡ 33   10.9 (7.2-14.5)*** 
Total 587   100 283   100 304   100 
 
Comparison of the distribution of patients with 
influenza-like illness in different age groups for each 
influenza season in both sexes, men and women: * p < 
0.001 versus other age groups, ** p < 0.001 vs. 0−4 
years old, λ p < 0.001 vs. 5−14 years old, *** p < 0.01 
vs. 0−4 years old, ‡ p < 0.001 vs. 0−4 years and p < 0.05 
vs. 5−14 years old, †p < 0.001 vs. 0−4 years old; ¶ 
p<0.005 vs. 0−4 years old, § p<0.05 vs. 0−4 years old 
 
Table 2: Percentage of patients with influenza-like illness declared by sentinel pharmacies not previously 




2017-2018 Influenza season 2018-2019 Influenza season 2019-2020 Influenza season 
No.    % (95% CI) n No.    % (95% CI) n No.    % (95% CI) n 
Both sexes       
0-4 years 1    12.5 (0.3−52.6) 8 5    23.8 (8.2−47.2) 21 10    30.3 (10.3−48.0) 33 
5-14 years 23    54.8 (38.5−71.0) 42 47    54.0 (45.0−65.1) 87 23    33.8 (21.8−45.8) 68 
15-64 years 481    72.4 (69.0−75.9) 664 553    71.5 (68.3−74.8) 773 298    69.5 (65.0−73.9) 429 
≥ 65 years 69    58.6 (47.3−65.8) 122 69    58.0 (48.7−67.3) 119 32    56.1 (42.4−69.9) 57 
Total 574    68.7 (65.5−71.9) 836 674    67.4 (64.4−70.3) 1,000 363    61.8 (57.8−65.8) 587 
Men       
0-4 years 1    25.0 (0.6−80.6) 4 3    23.1 (5.0−53.8) 13 4    22.2 (6.4−47.6) 18 
5-14 years 11    52.4 (28.6−76.1) 21 24    50.0 (34.8−65.2) 48 15    40.5 (23.4−57.7) 37 
15-64 years 232    75.3 (70.3−80.3) 308 269    73.7 (69.0−78.3) 365 141    69.1 (62.5−74.7) 204 
≥ 65 years 32    56.1 (42.4−69.9) 57 34    63.0 (49.1−76.8) 54 18    75.0 (53.3−90.2) 24 
Total 276    70.8 (66.1−75.4) 390 330    68.8 (64.5−73.0) 480 178    62.9 (57.1−68.7) 283 
Women       
0-4 years 0      0.0 (0.0−60.2) 4 2    25.0 (3.2−65.1) 8 6    40.0 (3.2−67.7) 15 
5-14 years 12    57.1 (33.6−50.7) 21 23    59.0 (42.2−75.7) 39 8    25.8 (42.2−42.8) 31 
15-64 years 249    69.9 (65.0−74.8) 356 284    69.6 (65.0−74.2) 408 157    69.8 (65.0−76.0) 225 
≥ 65 years 37    56.9 (44.1−69.7) 65 35    53.8 (41.0−66.7) 65 14    42.4 (41.0−60.8) 33 
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Table 3: Percentage of patients with influenza-like illness that sentinel pharmacies dispensed medications in 
Catalonia (Spain) in 2017-18, 2018-19 and 2019-20 influenza seasons. 
 
Age 
2017-2018 Influenza season 2018-2019 Influenza season 2019-2020 Influenza season 
No.    % (95% CI) n No.    % (95% CI) n No.    % (95% CI) n 
Both sexes       
0-4 years 7    87.5 (47.3−99.7) 8 21  100.0 (83.9−100) 21 31    93.9 (79.8−99.3) 33 
5-14 years 39    92.9 (80.5−98.5) 42 78    89.7 (82.7−96.6) 87 68  100.0 (94.7−100) 68 
15-64 years 631    95.0 (93.3−96.8) 664 743    96.1 (94.7−97.5) 773 423    98.6 (97.4−100) 429 
≥ 65 years 110    90.2 (84.5−95.9) 122 111    93.3 (88.4−98.2) 119 56    93.2 (90.6−100) 57 
Total 787    94.1 (92.5−95.8) 836 953    95.3 (93.9−96.7) 1,000 578    98.5 (97.4−99.5) 587 
Men       
0-4 years 3    75.0 (19.4−99.4) 4 13  100.0 (75.3−100) 13 18  100.0 (81.5−100) 18 
5-14 years 18    85.7 (63.6−96.9) 21 41    85.4 (74.4−86.4) 48 37  100.0 (90.5−100) 37 
15-64 years 292    94.8 (92.2−97.4) 308 353    96.7 (94.7−98.7) 365 202    99.0 (96.5−99.9) 204 
≥ 65 years 50    87.7 (78.3−97.1) 57 50    92.6 (82.1−97.9) 54 23    95.8 (78.9−99.9) 24 
Total 363    93.1 (90.4−95.7) 390 457    95.2 (93.2−97.2) 480 280    98.9 (96.9−99.7) 283 
Women       
0-4 years 4  100.0 (39.8−100) 4 8  100.0 (63.1−100) 8 13    86.7 (59.5−98.3) 15 
5-14 years 21  100.0 (83.9−100) 21 37    94.9 (82.7−99.4) 39 31  100.0 (88.8−100) 31 
15-64 years 339    95.2 (92.9−97.6) 356 390    95.6 (93.5−97.7) 408 221    98.2 (95.5−99.5) 225 
≥ 65 years 60    92.3 (82.9−97.4) 65 61    93.8 (85.0−98.3) 65 33  100.0 (89.4−100) 33 
Total 424    95.1 (92.9−97.2) 446 495    95.4 (93.5−97.3) 520 298    98.0 (96.4−99.7) 304 
 
Table 4: Drugs dispended by sentinel pharmacies to cases of influenza-like illness in Catalonia (Spain) in 2017-




season (n = 836) 
2018-2019 Influenza 
season (n = 1000) 
2019-2020 Influenza 
season (n = 587) 
2019-20 vs. 
2017-18 
OR (95% CI) No.    % (95% CI) No.    % (95% CI) No.    %  (95% CI) 
Paracetamol 605    72.4 (69.3−75.5) 750    75.0 (72.3−77.7) 492    83.8 (80.7−86.9) 1.97 (1.51−2.58)* 
Ibuprofen 231    27.6 (24.5−30.7) 270    27.0 (24.2−29.8) 170    29.0 (25.2−32.7) n. s. 
Acetil salicilic acid 32      3.8 (2.5−5.2) 30      3.0 (1.9−4.1) 12      2.0 (0.8−3.3) n. s. 
Cough medication 374    44.7 (41.3−48.2) 329    32.9 (29.9−35.9) 226    38.5(34.5−42.5) 0.77(0.62−0.96)*** 
Antihistamines 267    31.9 (28.7−35.2) 237    23,7 (21.0−26.4) 114    19.4 (16.1−22.7) 0.51(0.40−0.66)*** 
Ephedrine 111    13.2 (10.9−15.6) 126    12.6 (10.5−14.7) 68    11.6 (8.9−14.3) n. s. 
Antibiotic 66      7.9 (6.0−9.8) 72      7.2 (5.4−8-8) 22      3.7 (2.1−5.4) 0.45(0.28−0.74)** 
Antiseptic 35      4.2 (2.8−5.6) 41      4.1 (5.5−8.8) 20      3.4 (1.8−5.0) n. s. 
Mucolitic 73      8.7 (6.8−10.7) 67      6.7 (5.1−8.3) 53      9.0 (6.6−11.4) n. s. 
Homeopathic 5      0.6 (0.2−1.4) 2      2.0 (0.0−0.7) 1      0.2 (0.-0−0.9) n. s. 
Medicinal plants 34      4.1 (2.7−5.5) 34      3.4 (2.2−4.6) 22      3.7 (2.1−5.4) n. s. 
Bronco-dilator 24      2.9 (1.7−4.1) 21      2.1 (1.2−3.0) 18      3.1 (0.0−0.6) n. s. 
Trypsin 1      0.1 (0.0−0.7) 1      1.0 (0.0−0.6) 1      0.2 (0.0−0.9) n. s. 
Oseltamivir 3      0.4 (0.1−1.0) 1      1.0 (0.0−0.6) 6      1.0 (0.1−1.9) n. s. 
Anti-inflammatori 5      0.6 (0.2−1.4) 14      1.4 (0.6−2.2) 10      1.7 (0.6−2.8) n. s. 
OR: Odds Ratio, CI: confidence interval, n. s.: not significant OR 
* p < 0.001, ** p < 0.005, *** p < 0.05 
 
Table 5: Percentage of patients with influenza-like illness that physicians prescribed medications in Catalonia 
(Spain) in 2017-18, 2018-19 and 2019-20 influenza seasons. 
 
Age 
2017-2018 Influenza season 2018-2019 Influenza season 2019-2020 Influenza season 
No.    % (95% CI) n No.    % (95% CI) n No.    % (95% CI) n 
Both sexes       
0-4 years 7    87.5 (47.3−99.7) 8 15    71.4 (47.5−88.7) 21 23    69.7 (52.5−86.9) 33 
5-14 years 18    42.9 (26.7−59.0) 42 41    47.1 (36.1−58.2) 87 44    64.7 (51.7−75.8) 68 
15-64 years 175    26.4 (22.9−29.8) 664 237    30.7 (27.3−34.0) 773 133    31.0 (26.5−35.5) 429 
≥ 65 years 53    43.3 (34.2−52.6) 122 51    42.9 (33.5−52.2) 119 25    43.9 (30.1−57.6) 57 
Total 253    30.3 (27.1−33.4) 836 344    34.4 (31.4−37.4) 1,000 225    38.3 (34.3−42.3) 587 
Men       
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0-4 years 3    75.5 (19.4−99.4) 4 9    69.2 (69.2−90.9) 13 14    77.8 (52.4−93.6) 18 
5-14 years 9    42.9 (19.3−66.4) 21 23    47.9 (32.7−63.1) 48 21    56.8 (39.4−74.1) 37 
15-64 years 73    23.7 (18.8−28.6) 308 108    29.6 (24.8−34.4) 365 66    32.4 (25.7−39.0) 204 
≥ 65 years 26    45.6 (31.8−59.4) 57 21    38.9 (24.8−52.8) 54 6    25.0 (9.8−46.7) 24 
Total 111    28.5 (23.8−33.1) 390 161    33.5 (29.2−37.9) 480 107    37.8 (32.0−43.6) 283 
Women       
0-4 years 4  100.0 (39.8−100) 4 6    75.0 (34.9−96.8) 8 6    60.0 (16.3−67.7) 15 
5-14 years 9    42.9 (19.3−66.4) 21 18    46.2 (29.2−63.1) 39 8    74.2 (64.0−76.4) 31 
15-64 years 102    28.7 (23.8−33.5) 356 129    31.6 (27.0−36.2) 408 158    29.8 (8.8−42.8) 225 
≥ 65 years 27    41.5 (28.8−54.3) 65 30    46.2 (24.6−46.0) 65 19    57.6 (39.2−75.9) 33 
Total 142    31.8 (27.4−36.3) 446 183    35.2 (31.0−39.4) 520 118    39.8 (33.2−44.5) 304 
 
Table 6: Drugs prescribed by physicians to reported cases of influenza-like illness cases in Catalonia (Spain) in 




season (n = 836) 
2018-2019 Influenza 
season (n = 1000) 
2019-2020 Influenza 
season (n = 587) 
2019-20 vs.2017-18 
OR (95% CI ) 
No.    % (95% CI) No.    % (95% CI) No.    %  (95% CI) 
Paracetamol 183    21.9 (19.0−24.7) 249    24.9 (22.2−27.6) 181    30.8 (27.7−34.7) 1.59 (1.25−2.02)* 
Ibuprofen 93    11.1 (8.9−13.3) 128    12.8 (10.7−14.9) 100    17.0 (13.9−20.2) 1.64  (1.21−2.22)** 
Acetil salicilic acid 2      0.2 (0.0−0.9) 2      0.2 (0.0−0.7) 2      0.3 (0.0−1.2) n. s. 
Cough medication 100    12.0 (9.7−14.2) 81      8.1 (6.8−9.8) 58      9.9(7.4−12.4) n. s. 
Antihistamines 48      5.7 (4.1−7.4) 37      3,7 (2.4−4.9) 17      2.9 (1.4−4.3) 0.50(0.28−0.85)*** 
Ephedrine 3      0.3 (0.1−1.0) 15      1.5 (0.7−2.3) 4      0.7 (0.2−1.7) n. s. 
Antibiotic 66      7.9 (5.5−9.1) 72      7.2 (5.5−8.8) 22      3.7 (2.1−5.4) 0.45 (0.28−0.74)* 
Antiseptic 3      0.4 (0.1−1.0) 6      0.6 (0.1−1.1) 4      0.7 (0.2−1.7) n. s. 
Mucolitic 27      3.2 (2.0−4.5) 27      2.7 (1.6−3.7) 14      2.3 (1.1−3.7) n. s. 
Homeopathic 0      0.0 (0.0−0.4) 0      0.0 (0.0−0.4) 0      0.0 (0.0−0.6) n. s. 
Medicinal plants 1      0.1 (0.0−0.7) 0      0.0 (1.0−2.8) 3      0.5 (0.1−1.5) n. s. 
Bronco-dilator 22      2.6 (1.5−3.8) 19      1.9 (0.0−0.4) 12      2.0 (0.8−3.3) n. s. 
Trypsin 0      0.0 (0.0−0.4) 1      0.1 (0.0−0.6) 0      0.0 (0.0−0.6) n. s. 
Oseltamivir 3      0.4 (0.1−1.0) 1      0.1 (0.0−0.6) 6      1.0 (0.1−1.9) n. s. 
Anti-inflammatori 2      0.2 (0.2−1.4) 11      1.1 (0.4−1.8) 6      1.0 (0.1−1.9) n. s. 
OR: Odds Ratio, CI: confidence interval, n. s.: not significant OR * p < 0.001, ** p < 0.005, *** p < 0.05 
 
Table 7: Percentage of cases of influenza-like illness vaccinated against influenza during 2018-19 and 2019-20 
influenza campaigns. 
 
 Percentage of cases vaccinated against influenza 
 2018-19 Influenza campaign 2019-20 Influenza campaign 
Age No.    % (IC 95%) n No.    % (IC 95%) n 
0-4 years 0      0.0 (0.0−16.1) 21 0      0.0 (0.0−10.6) 33 
5-14 years 0      0.0 (0.0−4.1) 87 3      4.4 (0.9−12.4) 68 
15-64 years 26      3.4 (2.0−4.7) 773 15      3.5 (1.6−5.3) 429 
≥ 65 years 40    33.6 (24.7−42.5) 119 15    26.3 (14.0−38.6) 57 
Total 66      6.6 (5.0−8.2) 1,000 33      5.6 (3.7−7.6) 587 
Vaccine Effectiveness 
(≥ 65 years) 
51.4 (41.9−60.7)  67.1 (53.5−79.8)  
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The study found that influenza surveillance system based 
on sentinel pharmacies of Catalonia provided consistent 
information on influenza-like patients, medications 
dispensed and influenza epidemics in the three influenza 
seasons studied (2017-18, 2018-19 and 2019-20). The 
information obtained from sentinel pharmacies is 
complementary of the information provided by the 
network of sentinel physicians. 
 
The study found that 79-80% of influenza-like cases 
reported by sentinel pharmacies had 15-64 years of age 
and that less than 1% of cases had 0-5 years of age. In 
addition, only 12-14% of influenza-like cases reported 
by sentinel pharmacies in the three studied influenza 
seasons were derived to health centres for clinical 
assistance. These data indicate that most influenza-like 
patients attended by sentinel pharmacies were adults of 
working age with mild or moderate influenza-like illness, 
who were looking for influenza medication. 
 
The study found that 68.7% of influenza-like cases 
reported by sentinel pharmacies in 2017−18, 67.4% of 
patients reported in 2018−19 and 61.8% of patients 
reported in 2019−20 had not been detected previously in 
a medical visit. This data indicates that influenza 
morbidity and social and health impact of influenza 
could be underestimated based on the information 
obtained by current influenza surveillance systems. In 
addition, the fact that many patients with mild or 
moderate influenza-like illness solved the health problem 
with medications dispended by pharmacies without drug 
prescriptions showed that community pharmacies were 
acting as health managers and gatekeepers of the health 
system, reducing the impact of influenza on health 
services use and reducing public health resources for 
treating influenza patients.  
 
Sentinel pharmacies dispended medications 94-98% of 
patients with influenza like-illness attended by sentinel 
pharmacies during 2017-20. Medications dispended to 
more than 25% of patients included paracetamol, cough 
medications, ibuprofen and antihistamines. Other 
medications dispensed to less than 25% of patients 
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included antibiotics and oseltamivir. The dispensation of 
medications was quite similar in the three influenza 
seasons studied, except for antibiotics, paracetamol, 
cough medication and antihistamines. The variation in 
the dispensation of paracetamol, cough and 
antihistamines between 2017-18 and 2019-20 could be 
explained by a variation in patients preferences for 
influenza medication. The lower dispensation of 
antibiotics in 2019-20 than in 2017-18 is explained by 
the lower prescription of antibiotics to influenza patients 
in 2019-20.   
 
Physicians had prescribed medications to 30-38% of 
patients with influenza like-illness attended by sentinel 
pharmacies during 2017-20. Medications prescribed to 
more than 8% of patients included paracetamol, cough 
medications and ibuprofen. Other medications prescribed 
to less than 8% of patients included antibiotics, 
antihistamines and oseltamivir. The prescription of 
medications was quite similar in the three influenza 
seasons studied, except for antibiotics, paracetamol, 
ibuprofen, and antihistamines. The variation in the 
dispensation of paracetamol, ibuprofen and 
antihistamines between 2017-18 and 2019-20 could be 
explained by a variation in physician or patient 
preferences for influenza treatment. The reduction in the 
prescription of antibiotics between 2017-18 and 2019-20 
could be explained by a lower frequency of influenza 
complications in 2019-20 than in 2017-18 and 2018-19. 
 
The study found that 6.6% of influenza-like patients 
reported by sentinel pharmacies in 2018-19 and 5.6% of 
patients reported in 2019-20 had received influenza 
vaccines. Sixty per cent of vaccinated patients in 2018-
19 and 45% in 2019-20 had received influenza vaccine 
for the recommendation addressed to people of 65 or 
more years. Influenza vaccination effectiveness in 
individuals aged 65 or more years obtained in this study 
using the screening method was 51.4% in 2018-19 and 
67.1% in 2019-20. The influenza vaccination 
effectiveness obtained in this study for 2018-19 was not 
statistically different than the effectiveness of influenza 
vaccination in preventing influenza-like illness obtained 
by Vua et al.
[12]
 (35%; 95% CI: 19-47%) obtained in a 
meta-analysis carried out in 2002. By contrast, the 
influenza vaccination effectiveness obtained for 2019-20 
was higher than the effectiveness obtained by Vua et al.
12
 
Nevertheless, it is difficult to compare the influenza 
vaccination effectiveness obtained in this study with the 
effectiveness obtained in the meta-analysis carried out by 
Vua et al. because the studies included in the meta-
analysis assessed influenza vaccination effectiveness in 
patents with influenza-like illness attended in health 
centres.  
 
The influenza epidemic curves in 2017−18 and 2018−19 
obtained from sentinel pharmacies were quite similar to 
those obtained from sentinel physicians-based influenza 
surveillance, although the sentinel pharmacies-based 
influenza surveillance was able to detect the start of the 
influenza epidemic one week before in 2017−18 and two 
weeks before in 2018−19, compared with sentinel 
physicians-based influenza surveillance. The start and 
end of the influenza epidemics detected by sentinel 
pharmacies surveillance were from week 50 of 2017 to 
week 7 of 2018 and from week 51 of 2018 to week 8 of 
2019, while sentinel physicians surveillance detected 
start and end of the epidemic from week 53 of 2017 to 
week 9 of 2018 and from week 2 of 2019 to week 9 of 
2019. Nevertheless, it is difficult to compare the start and 
end of influenza epidemics obtained for sentinel 
pharmacies surveillance and sentinel physicians 
surveillance because the sentinel physicians surveillance 
decided the start and end of the influenza epidemics 
when the influenza incidence estimated from declared 
influenza-like cases was above and bellow 278.2 per 
100.000 habitants in 2017−18
13
 and when it was above 




The information provided by the influenza surveillance 
system based on sentinel pharmacies was complementary 
of the information provided sentinel physicians. The 
influenza surveillance system based on sentinel 
physicians can obtain consistent information about 
influenza epidemics, while sentinel pharmacies can 
provide information about influenza-like patients who 
are looking for influenza medication but are not willing 
to receive medical assistance.  
 
The study has several limitations. Firstly, 41 sentinel 
pharmacies were selected and reported cases to the 
influenza surveillance information in the 2017−18 and 
2018−19 influenza seasons. A higher number of cases of 
influenza-illness could have been reported with a higher 
number of sentinel pharmacies participating in the study. 
Nevertheless, the analysis of the information collected 
from the sentinel pharmacies in 2017−18 and 2018−19 
showed that the information provided by the 41 sentinel 
pharmacies was sufficient to analyse the influenza 
epidemic and to assess influenza morbidity not assisted 
in health centres and medications used to treat influenza-
like cases during 2017−2019.Secondly, the number of 
influenza-like cases detected per week by sentinel 
pharmacies could be lower than the real number of cases 
if pharmacies were not able to detect all cases of 
influenza-like illness among attended persons. 
Nevertheless, to know these data it is necessary to 
develop a complex and costly study. 
 
In the last years, several syndromic surveillance systems 
have been developed for influenza and for other 
illnesses. The Triple project-S-AGE used qualitative and 
quantitative indicators of success to evaluate nine 
influenza syndromic surveillance systems developed in 
Europe.
[14]
 The quantitative indicators included the 
advancement in the detection of the start of the influenza 
epidemic and the validity of the system and the 
qualitative indicators included the flexibility and 
acceptability of the surveillance system. The study 
evaluated influenza syndromic surveillance systems 
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based in data collected in medical visits, urgent medical 
visits, queries in websites and telephonic queries. The 
study found that influenza syndromic surveillance 
systems were able to detect the start of the influenza 
epidemic a mean of 0.75 weeks before the traditional 
influenza surveillance. The success of the influenza 
syndromic surveillance systems could explain by the 
following factors: 1) utilization of preclinical 
information collection that was collected before 
confirming influenza cases; 2) subnational range of the 
influenza syndromic surveillance systems; and 3) 
utilization of no clinical information. Dailey et al.
15 
compared different surveillance systems and sources of 
data for influenza surveillance, finding that the early 
detection of the start of the influenza epidemic required 
to use no clinical data rated to influenza as well as 
clinical data collected in primary health care centers and 
urgencies. The success of influenza syndromic 
surveillance systems can be explained by the facts that 
they use the information on patients not attended by 
health centers due to mild or moderate influenza illness, 
and the information on influenza patients without 
microbiological confirmation.  
 
The results obtained in the studies assessing influenza 
syndromic surveillance systems suggest that the new 
influenza syndromic surveillance system developed in 
Catalonia (Spain) can improve the influenza surveillance 
and control because it is more rapid than the traditional 
influenza surveillance systems, and because it obtain 
information that could not be collected using traditional 




The study found that influenza surveillance system based 
on sentinel pharmacies of Catalonia provided consistent 
information on influenza-like patients, medications 
dispensed and influenza epidemics in the three influenza 
seasons studied.  
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